- Scinai Immunotherapeutics’ CDMO unit, Scinai Bioservices, has received a non-dilutive grant of approximately $246,000 from the Israel Innovation Authority to fund 66% of a project installing an advanced sterile fill-and-finish system.
- The new system will enhance small-scale, flexible GMP manufacturing, improving operational agility and capacity for early-stage biotech clients in Israel, the U.S., and Europe.
Scinai Immunotherapeutics Ltd. announced that its CDMO unit, Scinai Bioservices, has been awarded a non-dilutive grant of approximately NIS 809,000 ($246,000) from the Israel Innovation Authority (IIA). The grant will fund around 66% of a NIS 1.23 million ($373,000) project to acquire and install an advanced fill-and-finish system for sterile manufacturing. The investment addresses a gap in Israel’s biopharma sector, where many early-stage companies lack access to local, flexible GMP facilities.
The Jerusalem-based system is designed for diverse primary packaging formats with minimal reconfiguration, enabling rapid batch turnaround and efficient switching between campaigns. Installation and qualification are expected in Q1 2026, with commercial operation planned for Q2 2026. The upgrade will substantially enhance Scinai’s fill-and-finish capacity and operational flexibility for early-stage biotech clients.
The grant recognises Scinai’s role in strengthening Israel’s biopharma manufacturing infrastructure. As noted by the IIA, CDMO services provide early-stage pharmaceutical and academic teams with access to advanced facilities, equipment, and expertise without major capital investment. Scinai offers end-to-end CDMO solutions from early clone selection through GMP drug substance and product manufacturing for clients in Israel, the U.S., and Europe.
“This grant is a strong vote of confidence in Scinai Bioservices’ growing role as a cornerstone of Israel’s biopharma manufacturing ecosystem. The IIA’s support enables us to expand our fill-and-finish capacity and provide early-stage biotech companies in Israel and abroad with the kind of flexible, high-quality, and responsive CDMO partnership typically available only through large global players.”
said Amir Reichman, CEO of Scinai
Since launching CDMO operations in 2023, Scinai Bioservices has supported numerous biotech companies with small-batch, agile, and fully cGMP-compliant services.
